|
Study of Systemic Amyloidosis Presentation and Prognosis Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Study of Systemic Amyloidosis Presentation and Prognosis conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Study of Systemic Amyloidosis Presentation and Prognosis Clinical research trials and Study of Systemic Amyloidosis Presentation and Prognosis healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Study of Systemic Amyloidosis Presentation and Prognosis. Study of Systemic Amyloidosis Presentation and Prognosis Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Study of Systemic Amyloidosis Presentation and Prognosis clinical trial. Participants typically obtain the most effective healthcare available for their Study of Systemic Amyloidosis Presentation and Prognosis condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Systemic Amyloidosis Presentation and Prognosis  Study of Systemic Amyloidosis Presentation and Prognosis
Study of Systemic Amyloidosis Presentation and Prognosis
For Condition: Amyloidosis
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) , Indiana University Cancer Center
Synopsis: OBJECTIVES: I. Analyze prospectively the course of amyloid deposition in patients with primary, secondary, myeloma-associated, and hereditary amyloidosis. II. Determine abnormalities of humoral and delayed-type hypersensitivity in these patients. III. Identify prognostic factors in hereditary amyloidosis and develop tests for genetic defects associated with systemic amyloidosis. IV. Diagnose familial amyloidotic polyneuropathy (FAP) prior to symptom onset. V. Validate the correlation of low serum prealbumin and retinol binding protein levels with amyloidosis in patients with FAP.
Details: PROTOCOL OUTLINE: Patients receive a comprehensive evaluation with an emphasis on identifying prognostic and diagnostic factors. Assessments include gastrointestinal, renal, hematologic, dermatologic, cardiac, and serologic studies. Immunologic studies include antinuclear antibody, latex fixation, and serum and urine electrophoresis. Genetic trees are constructed using detailed family history data; blood and urine samples are routinely collected from relatives. Family members of patients with familial amyloidotic polyneuropathy type II (Indiana type) undergo a flexor retinaculum biopsy of the wrist.
Eligibility:
Study Type: Observational, Screening
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Systemic amyloidosis, i.e.: Primary, myeloma associated Secondary, e.g., associated with the following conditions: Rheumatoid arthritis Inflammatory bowel disease
Total Enrollment: 100
Location and Contact Information:
Overall Study Official:
MerrillBenson, Study Chair, Indiana University Cancer Center
Indiana University Cancer Center *Recruiting*
Indianapolis, Indiana, 46202-5265
United States
Recruiting Merrill Benson 317-278-3426
Additional Information:
Study ID Numbers: NCRR-M01RR00750-0062; IUSM-831215
Study Start Date: January 1979
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004374
Other Amyloidosis Studies:
1. Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
2. Study of Systemic Amyloidosis Presentation and Prognosis
Related Studies:
Other Amyloidosis Clinical Trials
Other Indiana Clinical Trials
Other Indianapolis Clinical Trials
Study of Systemic Amyloidosis Presentation and Prognosis
|
|
|
|
|
|
|
|
